| Oct 22 |
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
|
| Oct 3 |
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
|
| Sep 19 |
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
|
| Sep 17 |
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
|
| Sep 16 |
Looking Into Allarity Therapeutics's Recent Short Interest
|
| Sep 16 |
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
|
| Sep 13 |
Allarity Therapeutics announces new CFO
|
| Sep 13 |
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 11 |
Allarity Therapeutics executes 1-for-30 reverse stock split
|
| Sep 11 |
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
|
